276 related articles for article (PubMed ID: 29455652)
1. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.
Kashyap MK; Abdel-Rahman O
Mol Cancer; 2018 Feb; 17(1):54. PubMed ID: 29455652
[TBL] [Abstract][Full Text] [Related]
2. PTK7, a Catalytically Inactive Receptor Tyrosine Kinase, Increases Oncogenic Phenotypes in Xenograft Tumors of Esophageal Squamous Cell Carcinoma KYSE-30 Cells.
Shin WS; Park MK; Kim JH; Oh SW; Jang JY; Lee H; Lee ST
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216506
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
4. Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF.
Shin WS; Lee HW; Lee ST
FASEB J; 2019 Nov; 33(11):12960-12971. PubMed ID: 31490704
[TBL] [Abstract][Full Text] [Related]
5. Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma.
Kim JH; Shin WS; Lee SR; Kim S; Choi SY; Lee ST
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293051
[TBL] [Abstract][Full Text] [Related]
6. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
[TBL] [Abstract][Full Text] [Related]
7. miR-516b functions as a tumor suppressor by directly modulating CCNG1 expression in esophageal squamous cell carcinoma.
Zhao Y; Wang Y; Xing G
Biomed Pharmacother; 2018 Oct; 106():1650-1660. PubMed ID: 30119241
[TBL] [Abstract][Full Text] [Related]
8. Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration.
Xiao J; Yang W; Xu B; Zhu H; Zou J; Su C; Rong J; Wang T; Chen Z
BMC Cancer; 2018 Oct; 18(1):976. PubMed ID: 30314454
[TBL] [Abstract][Full Text] [Related]
9. PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma.
Park M; Yoon HJ; Kang MC; Kwon J; Lee HW
Tumour Biol; 2016 Oct; 37(10):14217-14224. PubMed ID: 27557627
[TBL] [Abstract][Full Text] [Related]
10. Etiology, cancer stem cells and potential diagnostic biomarkers for esophageal cancer.
Liu K; Zhao T; Wang J; Chen Y; Zhang R; Lan X; Que J
Cancer Lett; 2019 Aug; 458():21-28. PubMed ID: 31125642
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Sutter AP; Höpfner M; Huether A; Maaser K; Scherübl H
Int J Cancer; 2006 Apr; 118(7):1814-22. PubMed ID: 16217753
[TBL] [Abstract][Full Text] [Related]
12. Long Non-Coding RNA (lncRNA) Growth Arrest Specific 5 (GAS5) Suppresses Esophageal Squamous Cell Carcinoma Cell Proliferation and Migration by Inactivating Phosphatidylinositol 3-kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Wang G; Sun J; Zhao H; Li H
Med Sci Monit; 2018 Oct; 24():7689-7696. PubMed ID: 30368517
[TBL] [Abstract][Full Text] [Related]
13. PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma.
Liu K; Song G; Zhang X; Li Q; Zhao Y; Zhou Y; Xiong R; Hu X; Tang Z; Feng G
World J Surg Oncol; 2017 May; 15(1):105. PubMed ID: 28545451
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA‑675‑3p promotes esophageal squamous cell cancer cell migration and invasion.
Xiao Q; Chen T; Wu Y; Wu W; Xu Y; Gong Z; Chen S
Mol Med Rep; 2018 Oct; 18(4):3631-3640. PubMed ID: 30106155
[TBL] [Abstract][Full Text] [Related]
15. TAB3 promotes human esophageal squamous cell carcinoma proliferation and invasion via the NF‑κB pathway.
Zhao J; Gai L; Gao Y; Xia W; Shen D; Lin Q; Mao W; Wang F; Liu P; Chen J
Oncol Rep; 2018 Nov; 40(5):2876-2885. PubMed ID: 30226617
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
17. ESCC ATLAS: A population wide compendium of biomarkers for Esophageal Squamous Cell Carcinoma.
Tungekar A; Mandarthi S; Mandaviya PR; Gadekar VP; Tantry A; Kotian S; Reddy J; Prabha D; Bhat S; Sahay S; Mascarenhas R; Badkillaya RR; Nagasampige MK; Yelnadu M; Pawar H; Hebbar P; Kashyap MK
Sci Rep; 2018 Aug; 8(1):12715. PubMed ID: 30143675
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of receptor tyrosine kinase activation in cancer.
Du Z; Lovly CM
Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines.
Hartmans E; Linssen MD; Sikkens C; Levens A; Witjes MJH; van Dam GM; Nagengast WB
Oncotarget; 2017 May; 8(18):29846-29856. PubMed ID: 28415738
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.
Peron M; Lovisa F; Poli E; Basso G; Bonvini P
PLoS One; 2015; 10(7):e0132330. PubMed ID: 26147305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
